期刊文献+

塞来昔布对H22肝癌组织环氧合酶2及磷脂酶A2抑制作用 被引量:4

The inhibitory effect of celecoxib on H22 hepatoma and its mechanism
下载PDF
导出
摘要 目的考察塞来昔布对小鼠H22肝癌细胞移植瘤生长的抑制作用,并探讨其作用机制。方法40只BALB/c小鼠腋下接种H22肝癌细胞,然后随机分为对照组和低、中、高剂量(100、200、400mg/kg)组,于接种后3天灌胃给药,连续用药15天后处死,计算肿瘤的体积和重量;Western blot法检测瘤组织中胞浆磷脂酶A2和环氧合酶2的表达。结果塞来昔布低、中、高剂量治疗组的小鼠平均瘤重均低于对照组,与对照组相比较有显著性差异(P<0.05)。塞来昔布治疗组抑瘤率均大于30%,其中高剂量治疗组的抑瘤率大于75%,作用明显。塞来昔布能够明显抑制胞浆磷脂酶A2和环氧合酶2的表达,具有剂量依赖关系。结论塞来昔布对H22肝癌具有抑制作用,其机制可能是通过抑制胞浆磷脂酶A2及环氧合酶2的表达而发挥抗肿瘤的作用,二者在此过程中具有协同效应。 Objective To investigate the inhibitory effect of celecoxib on the growth of transplanted mouse H22 hepatoma in BALB/c mice in wvo and its anticarcinogenic mechanism. Methods Forty BALB/e mice receiving tumor implantation were divided randomly into control group and eelecoxib groups at low, middle, high dosage (100,200,400 mg/kg).All the groups were garaged continuously with normal saline or celeeoxib on the third day after implantation. The mice were killed on the 15th day, and the volume and weight of the tumor tissues were calculated. The protein expressions of cytosolic phospholipase A2 and cyelooxygenase-2 were examined in the tumor tissues by Western blot analysis. Results The solid tumor volume and weight of treatment groups were lower than those of control group, and there was significant difference among the groups ( P 〈 0.05). The tumor inhibitory ratios of treatment groups were more than 30%, especially 75% in high dose group. The protein expressions of cytosolic phospholipase A2 and eyelooxygenase-2 in treatment groups were lower than control group in a dose-dependent mariner. Conclusion Celecoxib can inhibit the growth of transplanted H22 hepatoma in dose-dependent manner. The anticarcinogenic effect of celecoxib depends on not only inhibit- ing the expressing of cyclooxygenase-2, but also the synergistic effect of cytosolic phospholipase A2 and cyclooxygenase-2.
出处 《中国实验诊断学》 北大核心 2010年第2期174-176,共3页 Chinese Journal of Laboratory Diagnosis
基金 长春市科技计划项目(2007126)
关键词 塞来昔布 H22肝癌 胞浆磷脂酶A2 环氧合酶-2 celecoxib H22 hepatoma cytosolic phospholipase A2 cyclooxygenase-2
  • 相关文献

参考文献10

  • 1Dannenberg AJ, Altorki NK, Boyle JK, et al. Cyelooxygenase2: A pharmacological target for prevention of cancer [ J ]. Lancet Oncol, 2001,2 (9) : 544. 被引量:1
  • 2Cui W, Hu SX, Tang ZY, et al. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX- 2-deleted human HCC xenografts in nude mice [ J]. Anticancer Drugs, 2008,19: 891. 被引量:1
  • 3Schonthal AH. Induction of apoptosis by celecoxib in cell culture: an uncertain role for cyclooxygenase-2 [J]. Cancer Res,2007,67: 5575. 被引量:1
  • 4刘纯伦 欧武陵.塞来昔布对肝癌SMMC27721细胞的生长抑制作用.第三军医大学学报,2006,8(26):682-682. 被引量:1
  • 5俞万钧,修清玉,李兵,石昭泉,方正,黄海.塞来昔布对Lewis肺癌的抑制作用[J].第二军医大学学报,2005,26(5):505-508. 被引量:3
  • 6Yano T, Zissel G, Mtdler-Qemheim J, et al. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via KP3 [J]. FELLS Lett,2002,518(1-3 ) : 154. 被引量:1
  • 7Pai R,Soreghan B,Szabo H,et al. Prostaglandin E2 tranactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastreintestinal hypertrophy[J]. Nat Med,2002,8(3) :289. 被引量:1
  • 8Herrmann C, Block C, Geisen C, et al. Sulindac sulfide inhibits Ras signaling[J].Oncogene, 1998,17(14) : 1769. 被引量:1
  • 9Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-KappaB pathway [ J ]. J Biol Chem, 1999,274 ( 38 ) : 27307. 被引量:1
  • 10Mayo MW, Wang CY, Congswell PC, et al. Requirement of NF-kappa Bactivation to suppress p53-independent apoptosis induced by oncogenic Ras [J]. Science, 1997,278(5344) : 1812. 被引量:1

二级参考文献10

  • 1Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage Ⅰ non-small cell lung cancer[J]. Clin Cancer Res, 2001, 7(4):861-867. 被引量:1
  • 2Harris RE, Beebe DJ, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers[J]. Oncol Rep, 2002, 9(4):693-695. 被引量:1
  • 3Rahman MA, Dhar SK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver[J]. Clin Cancer Res, 2001, 46(5):1325-1332. 被引量:1
  • 4Toyoaki H, Yasushi Y, Hiroyuki A, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinoma[J]. Cancer Res, 1998, 58:3761-3764. 被引量:1
  • 5Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung[J]. Lung Cancer, 2000,30(2):73-81. 被引量:1
  • 6Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas[J]. Gastroenterology, 1994, 107:1183-1188. 被引量:1
  • 7Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth[J]. J Clin Invest, 2000, 105(11):1589-1594. 被引量:1
  • 8Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia[J]. Ann Clin Lab Sci, 2000, 30(1):3-21. 被引量:1
  • 9Tsujii M, DuBois RN. Alterations is cellular adhesion and apoptosis in epithelial cells overexpression cox-2[J]. Cell, 1995, 83:493-499. 被引量:1
  • 10Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors[J]. Cancer Res, 2000, 60(5):1306-1311. 被引量:1

共引文献2

同被引文献55

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部